Microbes in Your Mouth May Impact Your Risk of Cognitive Decline
In a study of 55 participants with mild cognitive impairment (MCI), those who hosted a relatively high abundance of bacteria from the genus Neisseria in their mouths had better working memory, executive function, and visual attention.
Even among 60 people without cognitive decline, when Neisseria dominated the oral microbiome, working memory scores improved.
The current study, led by researchers at the University of Exeter in the UK, suggests that by promoting certain bacteria in the mouth we could potentially delay cognitive decline. This could be achieved with probiotics or prebiotics that can boost and feed certain microbial communities in the oral cavity within just weeks.
The findings align with other recent studies, which suggest the cause of dementia may be coming from inside the mouth.
In recent years, for instance, poor oral health has emerged as a major risk factor for cognitive decline. Scientists have even found some bacteria linked to gum disease in the brains of those who have died from Alzheimer's.
Still, not all microbes in the mouth are necessarily harmful to the brain; some could be protective, too. Similar to bacteria in the gut, a nicely balanced microbiome is key.
The Neisseria genus includes more than 20 species of bacteria, many of which typically live in the nose and mouth quite peacefully and may even confer health benefits.
Recently, studies have found Neisseria bacteria can lower a person's systemic blood pressure by helping to convert nitrate-rich foods (usually vegetables) to nitric oxide.
Nitric oxide is a key signaling molecule in the body, which protects against gum disease and helps control and regulate blood pressure, as well as our cardiovascular response to exercise. It could also help keep the brain healthy.
Based on recent evidence, some neuroscientists suspect nitric oxide may protect the central nervous system by boosting neural plasticity and improving the efficiency and power of neural messages. The signaling molecule may even reduce neural inflammation – a central mechanism of Alzheimer's.
Intriguingly, people who are genetically predisposed to Alzheimer's tend to have trouble naturally producing nitric oxide.
In the current study, molecular biologist Joanna L'Heureux and her colleagues found that of 33 participants with MCI who were genetically predisposed to Alzheimer's, many had oral microbiomes dominated by the Prevotella genus and not the Neisseria genus.
One species of Prevotella in particular, P. intermedia, was a predictor for an elevated genetic risk for dementia. This suggests it could be used as an early marker of disease risk.
In the study, when the Prevotella genus reigned, there was less nitrate available in the mouth to convert to nitric oxide, probably because Prevotella uses the nitrate for other means.
Thus, by promoting Neisseria and eradicating Prevotella in the mouth, the authors of the study think they could potentially influence nitric oxide availability, thereby influencing the health of the brain.
Nitrate-rich diets, like the Mediterranean diet, are linked to improved brain health, but further research is needed to understand the link between what we put in our mouths, our oral microbiome, and the major signaling molecules produced by those microbes.
A 2021 study in healthy older people, for instance, found a correlation between oral microbiomes dominated by Neisseria (and a co-occurring genus, called Haemophilus) and sustained attention, even when the amount of dietary nitrate changed.
Other research has linked higher rates of Neisseria to younger age, lower body mass index, fewer teeth with damage, and not smoking.
"Collectively, these results indicate that a high relative abundance of bacteria belonging in the Neisseria–Haemophilus module is associated with better cognitive outcomes in individuals with MCI as well as in healthy older people," conclude L'Heureux and her team.
The study was published in PNAS Nexus.
Tuberculosis Outbreak in Kansas Is Among Largest on Record in US
Scientists Confirm a New Strain of Bird Flu Has Emerged in The US
Exercise Doesn't Burn as Many Calories as You Think, Experts Say
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
4 hours ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
Yahoo
7 hours ago
- Yahoo
Early results from major clinical trial show healthy lifestyle slows cognitive decline
Phyllis Jones wakes up every morning to work up a sweat in countries all over the world, 'and even sometimes on the moon,' she said, thanks to her favorite workout gadget, a virtual reality headset. Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up. She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said. She was probably also destined to lose her ability to think clearly. Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too. 'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.' Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer. Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables. The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information. After two years, both groups showed progress. But people in the structured group saw greater benefits. 'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina. 'This is what's giving folks additional resilience against cognitive decline,' she said. Greater support and accountability in the structured group were key benefits. 'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto. The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health. It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia. While some drugs may slow how quickly dementia develops, there is no cure. 'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida. The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research. This isn't the only study to link lifestyle to a delay in dementia. Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's. The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside. 'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said. POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain. Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association. 'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said. Jones is eager to see those results when they're available. 'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol. 'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.' This article was originally published on Solve the daily Crossword
New York Post
9 hours ago
- New York Post
Lower your dementia risk with these 2 simple routines — you can even choose how hands-on you want to be
Keep this in mind. Some 22% of adults 65 and older are believed to have trouble with their memory and thinking, also known as mild cognitive impairment (MCI). Individuals with MCI can perform most everyday activities and generally manage their own care. Advertisement 4 Dementia is a growing problem in the US. While there's no cure, treatments and therapies can help manage symptoms and potentially slow disease progression. Robert Kneschke – An additional 10% of older adults are estimated to have dementia, which is more severe, interfering with daily life and threatening independence. The number of new dementia cases is projected to double by 2060, primarily due to the aging population. Advertisement Now, new Alzheimer's Association research — known as the POINTER study — finds that two special programs can protect against age-related cognitive decline in older adults. 'As the burden of dementia grows worldwide, US POINTER affirms a vital public health message: healthy behavior has a powerful impact on brain health,' said Alzheimer's Association President and CEO Joanne Pike. 4 The two-year POINTER trial evaluated the effectiveness of two 'lifestyle interventions' that emphasized physical activity, nutrition, brain exercises, social engagement and heart health monitoring. – Advertisement Research has suggested that about 40% of dementia cases could be prevented or delayed by addressing 14 modifiable risk factors — alcohol abuse, smoking, diabetes, obesity, high blood pressure, air pollution, brain injury, physical inactivity, depression, social isolation, hearing loss, lower levels of education, high cholesterol and vision loss. The two-year POINTER trial evaluated the effectiveness of two 'lifestyle interventions' that emphasized physical activity, nutrition, brain exercises, social engagement and heart health monitoring. About 2,100 participants between 60 and 79 years old and at high risk of cognitive decline were split into two groups. With the self-guided lifestyle intervention, participants attended six peer team meetings that encouraged behavioral changes. Advertisement Study staff provided general support but not goal-directed coaching. 4 Here's a look at how the two programs fared in terms of change in cognitive function. Alzheimer's Association The structured lifestyle intervention was more intense, goal-oriented and supportive. Participants attended 38 peer team meetings over two years and received detailed recommendations for aerobic resistance and stretching exercises. They were directed to follow the brain-healthy MIND diet and keep their noggin' engaged with memory, attention and speed exercises. A study clinician often reviewed their health metrics and goals with them. About 89% of participants completed the final two-year assessment. Advertisement Cognitive function scores increased in both groups. The structured lifestyle intervention had better results, protecting the brain for up to two years. The findings were presented Monday at the Alzheimer's Association International Conference in Toronto and published in the Journal of the American Medical Association (JAMA). There's no cure for dementia, but treatments and therapies can help manage symptoms and potentially slow disease progression. 4 The MIND diet emphasizes natural, plant-based foods and not processed foods, saturated fats or red meat. bit24 – Advertisement 'The positive results of US POINTER encourage us to look at the potential for a combination of a lifestyle program and drug treatment as the next frontier in our fight against cognitive decline and possibly dementia,' Pike said. The Alzheimer's Association invested nearly $50 million to lead POINTER, with the National Institute on Aging at the National Institutes of Health chipping in for extra research. The Alzheimer's group plans to spend an additional $40 million over the next four years to track POINTER participants and introduce brain-healthy initiatives across America. 'While not everyone has the same access or ability to adhere to more intensive behavior interventions, even modest changes may protect the brain,' said Laura D. Baker, POINTER principal investigator and Wake Forest University School of Medicine professor.
